טוען...
Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects
BACKGROUND: To prospectively analyze the efficacy of uromune® in the prevention of uncomplicated recurrent urinary tract infections at 3 and 6 months, and according to gender and menopause. METHODS: From September 2011 to December 2017 uromune® was administered sublingually every 24 h along 3 months...
שמור ב:
| הוצא לאור ב: | BMC Infect Dis |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6819445/ https://ncbi.nlm.nih.gov/pubmed/31660885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-019-4541-y |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|